Latest news with #AmericanAssociationofNeurologicalSurgeons
Yahoo
08-07-2025
- Health
- Yahoo
Hope on the Horizon: Cutting-Edge Therapies Redefine Outcomes in Glioblastoma Multiforme Treatment making the global market to nearly double by 2033 and grow with a CAGR of 8.5%
The glioblastoma multiforme treatment market is expected to grow significantly and reach USD 6.1 billion by 2033, driven by a rising prevalence, growing R&D investment in novel therapies and favorable reimbursement support. New vaccine-based approaches are emerging as key areas of focus. Chicago, July 08, 2025 (GLOBE NEWSWIRE) -- The global glioblastoma multiforme treatment market was valeud at US$ 3.0 billion in 2024 and is expected to reach USD 6.1 billion by 2033, growing at a CAGR of 8.5% from 2025-2033. This expansion is fueled by rising disease prevalence, advances in diagnostics, growing R&D investments, and emerging targeted therapies. However, challenges such as the blood-brain barrier, therapeutic resistance, and limited long-term efficacy constrain progress and deter commercial investment. Despite these hurdles, innovation across therapeutic modalities and supportive technologies is gradually reshaping the treatment landscape. Explore Key Data Points and Forecast Tables in the Free Sample Copy: Glioblastoma Multiforme is the most common type of cancerous brain tumor. It poses significant treatment challenges due to its rapid proliferation, invasive growth, and resistance to conventional therapies. It is characterized by necrosis, microvascular proliferation, and marked cellular atypia. As per the American Association of Neurological Surgeons in 2024, glioblastoma multiforme accounted for 47.7% of malignant brain and CNS tumors, with an incidence of 3.2 per 100,000 and a prevalence of 9.2 per 100,000 in the U.S. According to the National Brain Tumor Society, the median survival is 14.6 months, with only 17% of patients alive after two years and a five-year survival rate of just 6.8%. It is more common in males, peaks between ages 75 – 84, and shows racial disparities, with highest incidence among non-Hispanic white populations. Treatment typically involves surgical resection followed by chemoradiation with temozolomide, which remains the standard of care (SoC). However, recurrence occurs in over 90% of patients within two years. For recurrent cases, bevacizumab (Avastin) and combinations like lomustine-bevacizumab offer modest benefits. Device-based therapies, such as Tumor Treating Fields (TTFields), continue gaining traction with FDA-approved systems like Optune Gio. Novel therapies, including selinexor (NCT04216329) and immune checkpoint inhibitors like nivolumab (NCT04606316), are currently in clinical trials, signaling progress towards durable Forecast (2033) USD 6.1 billion CAGR 8.5% Top Driver (s) Growing Prevalence of glioblastoma multiformeFavorable reimbursement policies Demand for effective treatment Top Trend Adoption of TTFields devices Top Restraint Consistently low survival rates in glioblastoma multiforme Opportunity Unlocked: Glioblastoma Vaccines as the Next Frontier in Immunotherapy Glioblastoma multiforme is hard to treat with conventional therapies. However, breakthroughs in vaccine-based immunotherapy are beginning to reshape the therapeutic landscape, offering new hope for the patients. Research efforts are accelerating around multiple vaccine platforms, including peptide-based, dendritic cell (DC), and mRNA vaccines, highlighting a new era of personalized and immune-driven treatment strategies. Peptide vaccines, such as SurVaxM developed by MimiVax and currently in Phase II clinical trials, are designed to target tumor-specific neoantigens, activating the immune system to selectively attack malignant cells. These personalized vaccines have shown potential in extending progression-free survival and enhancing immune engagement. Similarly, DC vaccines are gaining traction, despite logistical challenges in integration with standard therapies. Notable candidates such as DCVax-L, in Phase III trials for newly diagnosed and recurrent glioblastoma multiforme, and DOC1021, currently in Phase II trials by Diakonos, have demonstrated improved two-year survival rates when administered sequentially after temozolomide (TMZ) chemotherapy, rather than concurrently. Meanwhile, mRNA-based vaccines are emerging as a powerful immunotherapeutic modality, leveraging their rapid development cycle and capacity to induce strong, targeted immune responses against glioblastoma multiforme cells. Their adaptability and precision position them as a key component in next-generation oncology protocols. While the momentum is promising, ongoing research aims to refine delivery systems, address tumor-induced immunosuppression, and explore synergistic combinations with checkpoint inhibitors and standard-of-care therapies. Collectively, the expanding pipeline of glioblastoma vaccines signifies a paradigm shift toward more personalized, immune-based interventions, marking a transformative step forward in the quest for more durable and effective glioblastoma multiforme treatment. Regional Dynamics Shaping the Glioblastoma Multiforme Treatment Landscape The global glioblastoma multiforme treatment market is evolving rapidly, with regional dynamics playing a pivotal role in shaping its growth. North America leads the market, driven by advanced healthcare infrastructure, streamlined regulatory frameworks, and strong R&D investment. The U.S. Consolidated Appropriations Act of 2024 allocated $10 million to establish the Glioblastoma Research Program (GBMRP) under CDMRP, while Canada's Lundin Cancer Fund committed $4 million in 2025 to launch a national glioblastoma multiforme initiative, reinforcing the region's leadership in clinical innovation. Europe follows closely, propelled by coordinated national research strategies and strong public funding. Germany's UNITE Glioblastoma project, supported by the German Research Foundation's Collaborative Research Centers, exemplifies the region's growing commitment to tackling glioblastoma multiforme through advanced research and cross-border collaboration. The Asia-Pacific region is witnessing rapid progress, with governments, academia, and private stakeholders stepping up investment. Japan's conditional approval of DELYTACT (G47∆) the world's first oncolytic virus therapy for malignant gliomas, highlights the region's increasing role in therapeutic innovation. Meanwhile, the Middle East and Africa are in the early stages of glioblastoma multiforme research development. Though challenged by limited infrastructure and funding, emerging efforts from academic centers and private healthcare providers are laying the groundwork for future growth and capacity-building. As glioblastoma multiforme remains one of the most aggressive brain cancers, regional efforts will continue to shape the global response, advancing innovation, access, and treatment outcomes. Recent Advancements and Key Players in the Glioblastoma Therapeutics Market Several prominent players, including Novocure, Roche, Merck & Co., Novartis, Daiichi Sankyo, Allergan, Laminar Pharmaceuticals, Vigeo Therapeutics, Eli Lilly, Incyte Corporation, Kazia Therapeutics, and TVAX Biomedical, are advancing innovation in the glioblastoma treatment landscape. These companies are focused on developing novel therapeutics, targeted drug delivery systems, and strategic collaborations to tackle one of the most aggressive forms of brain cancer. In March 2025, Laminar Pharmaceuticals announced promising results from its ongoing Phase 2b/3 clinical trial (NCT04250922) of LAM561 in newly diagnosed glioblastoma (ndGBM). The randomized, double-blind, placebo-controlled study evaluates LAM561 in combination with standard chemoradiotherapy (radiotherapy and temozolomide). Early data revealed a positive trend in progression-free survival (PFS), particularly in patients with MGMT-methylated tumors. The trial is partially supported by the EU H2020 ClinGlio initiative, reinforcing the importance of public-private partnerships in advancing brain cancer research. Similarly, on June 2, 2025, Sapience Therapeutics presented updated clinical and biomarker data from its ongoing Phase 2 trial of Lucicebtide (formerly ST101) at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Lucicebtide, a first-in-class C/EBPβ antagonist, demonstrated encouraging results in glioblastoma patients, further validating its mechanism of action and potential as a novel targeted therapy. Further driving progress, on April 1, 2025, Spanios and GlioGuard announced a strategic partnership to accelerate glioblastoma drug discovery and development. This collaboration aims to deliver more effective and personalized treatment options for glioblastoma multiforme, addressing the urgent need for breakthroughs in one of the most treatment-resistant forms of cancer. These advancements highlight the growing momentum in glioblastoma therapeutics. With continued innovation, clinical progress, and collaborative efforts, the industry is poised to improve patient outcomes and reshape the future of brain cancer treatment. Book a 1:1 Presentation to Discuss Key Trends and Strategic Takeaways: Future Outlook: Evolving the Glioblastoma Multiforme Treatment Landscape The glioblastoma multiforme treatment market is under transformation. By 2030, a combination of drug innovation, device advancement, and integrated care models is expected to redefine survival outcomes for this aggressive brain cancer. Oral therapies currently lead the market, driven by ease of use and improved patient adherence. Injectables follow, offering systemic options like chemotherapies and targeted biologics. Implants, such as localized wafers, remain a niche but vital component post-surgery. Therapies, especially multi-modal regimens, dominate the market and are expanding rapidly, as combination approaches become the clinical standard. The next wave will be led by immunotherapies and immune checkpoint inhibitors, poised to break the disease immune resistance. These emerging treatments will increasingly complement traditional modalities, aiming for longer progression-free and overall survival. Wearable devices, particularly Novocure's Optune Gio, represent a paradigm shift. Future versions will be lighter, more personalized, and AI-integrated, enabling real-time therapy adjustments and remote monitoring, bringing glioblastoma multiforme care closer to the patient. Key Competitors Novocure Roche Merck & Co. Novartis Daiichi Sankyo Allegran Laminar pharmaceuticals Vigeo therapeutics Eli lily Incyte corporation Kazia Therapuetics TVAX Biomedicals Segmentation: Glioblastoma Multiforme Treatment Market By Treatment Type Surgery (Gliadel wafer) Therapies Chemotherapy Temzolomide Lomustine Radiation Therapy Targeted Therapy (Bevacizumab) Others (Delytact) Tumor Treating Fields (TTF) (Optune Gio) By Dosage Form Oral Injectables Implant and TFF Field Device By End Users Hospitals & Clinics (specialty clinics) Cancer Treatment Centers Academic and Research Organizations By Region North America South America Europe Asia Pacific Middle East and Africa Still Have Questions? Contact Us for Clarification or a Custom Data Request: About Astute Analytica Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements. With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace. Contact Us:Astute AnalyticaPhone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)For Sales Enquiries: sales@ Follow us on: LinkedIn | Twitter | YouTube CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: sales@ Website: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23-05-2025
- Health
- Yahoo
Uche Ojeh, Husband Of ‘TODAY' Show Co-Host Sheinelle Jones, Dies Of Brain Cancer
Uche Ojeh, husband of TODAY co-host Sheinelle Jones, has died after a battle with brain cancer. The news was shared on the news program on Friday (May 23) morning. Ojeh, whose full name is Uchechukwuka Adenola Ojeh, was 45 years old at the time of death. The couple met in college at Northwestern University in the 1990s. Jones, an 18-year-old freshman at the time, offered to take high school senior Ojeh on a campus tour. From there, they dated for eight years before he proposed at their alma mater. In total, the couple were married for 17 years and have three children: 15-year-old Kayin, and 12-year-old twins, Uche and Clara. 'There are no words for the pain we feel for Sheinelle and their three young children. Uche was an incredible person. We all loved him. And so we want to take a moment to tell you more about the remarkable man who was Sheinelle's perfect partner in life,' reflected TODAY co-host Savannah Guthrie. 'One thing he always talked about — he talked about those kids,' added co-host Craig Melvin. 'He loved those kids more than anything else in this world, and was just so proud. He was that dad that was on the sideline at every soccer game. He was at all the concerts, the recitals. He was that guy, and they had such a beautiful love story.' According to the American Association of Neurological Surgeons (AANS), Glioblastoma (GBM) is a fast-growing and aggressive brain tumor, often referred to as a grade IV astrocytoma. GBM is the most common malignant brain and other CNS tumors, accounting for 47.7% of all cases. The cancer has a low survival rate, with approximately 40% survival in the first year post-diagnosis and 17% in the second year. It can result in death in six months or less, if untreated. Earlier this year, Jones took time off from the program to deal with a 'family health matter,' with the support of her TODAY family. 'Thank you, for all of your love and support,' shared Jones on Instagram Friday morning, uploading the emotional morning segment. VIBE sends our condolences to the family and friends of Uche Ojeh. More from Philly Rapper LGP Qua Dead At 30 Following Fatal Mother's Day Shooting Ice Cube Acknowledges Late 'Friday' Stars As Franchise Moves Forward Mia Love, First Black Republican Congresswoman, Dead At 49
Business Wire
28-04-2025
- Health
- Business Wire
Largest Real-World Study of Its Kind Highlights How RapidAI Aids in Identifying Challenging Aneurysms
SAN MATEO, Calif.--(BUSINESS WIRE)-- RapidAI, the gold standard in neurovascular AI-based clinical decision support and a leader in enterprise radiology solutions, today announced pivotal results from the most extensive real-world study to date on AI for aneurysm detection. Presented at the 2025 American Association of Neurological Surgeons (AANS) Annual Meeting, the retrospective, single-center study analyzed 11,694 consecutive CTA scans 1, demonstrating how RapidAI's clinically validated platform, Rapid Aneurysm, can enhance diagnostic confidence and consistency, particularly in detecting nuanced or hard-to-visualize intracranial anomalies such as aneurysms when used in conjunction with standard clinical interpretation. RapidAI helped identify nearly 23% more aneurysms than were noted on the original radiology reports. Share 'Detecting aneurysms is inherently challenging, especially in a busy practice when they're subtly positioned,' said Reza Dashti, MD, associate professor of neurosurgery and lead study investigator. 'This study shows how AI can augment clinical expertise and meaningfully advance diagnostic accuracy in real-world settings.' Presented at AANS, with additional analyses available in the abstract, the study is the most extensive retrospective, single-center AI validation for aneurysm detection to date. In the study, RapidAI helped identify nearly 23% more aneurysms than were noted on the original radiology reports. Those additional detections had a median size of 3.9 mm, large enough to warrant intervention in many cases. For those aneurysms ≥ 3mm in size, RapidAI demonstrated stand-out performance, reinforcing the value of its deep clinical AI in enhancing diagnostic accuracy and consistency while also enhancing clinical workflows. In this subset, the platform achieved a sensitivity of 92.5% and a specificity of 96.4%. 'Given the increasing demands on today's radiology teams, this study speaks to the potential of AI to offer meaningful support and capability enhancement to the real-world challenges of manual interpretation,' said David Stoffel, MD, chief business officer at RapidAI. 'This level of diagnostic aid for radiologists not only improves patient outcomes but also holds the potential to reduce downstream costs associated with missed or delayed aneurysm diagnoses.' RapidAI's aneurysm platform combines 3D visualization, growth tracking, and automated measurement, providing clinicians with a comprehensive view and confidence in their decisions. With this study, RapidAI not only demonstrates the value of AI in real-world care but also helps raise the bar for how hospitals and health systems can support their teams with tools for smarter, faster diagnostics. About RapidAI RapidAI is the world leader in AI-driven medical imaging analysis and coordinated care. With the industry's most validated clinical AI platform, we empower care teams to rapidly, precisely, and confidently manage life-threatening conditions. Trusted by thousands of hospitals in 100+ countries, RapidAI delivers the deepest level of clinical decision support on the market to help accelerate the time to treatment and enhance patient outcomes. We go beyond the algorithm to drive care team collaboration and efficiencies that expand access to life-saving interventions. At RapidAI, we establish new standards for care teams and the patients they treat.
Yahoo
26-03-2025
- Politics
- Yahoo
Mia Love's family announces funeral plans — Here's what to know, how to attend
Related video: First Black Republican congresswoman Mia Love dies at 49 SALT LAKE CITY () — The family of Mia Love has announced funeral plans for the former Utah congresswoman, who , after battling brain cancer. Love will lie in state at the Utah State Capitol Rotunda on Sunday, April 6, from 5:30 p.m. until 8:30 p.m., according to her . Members of the public have been invited to attend. Members of the public are also invited to attend Love's memorial services on Monday, April 7, starting at 10 a.m. The services will be held on the University of Utah's campus, at (1780 S. Campus Dr. in Salt Lake). Love is survived by her husband, children, parents, siblings, and grandchildren. Her family has asked that, in place of flowers, people donate to the , or to the . What is glioblastoma, the aggressive brain cancer that killed former US Rep. Mia Love? In 2022, Love was diagnosed with glioblastoma, which is described by the American Association of Neurological Surgeons as '.' At the beginning of March 2025, Love's family posted on social media to say that the . 'The absence of her physical presence is real and very difficult,' Love's obituary reads. 'However, the words her voice lifted up and the life she lived will amplify the principles she believed far into eternity.' Love was born in December 1975 to Haitian immigrant parents. She was the first Black Republican woman to be elected to United States Congress, and was also the mayor of Springville and a CNN commentator throughout her career. 'Mia Love was a fearless leader, a history-maker, and a woman of deep conviction,' Lt. Gov. Deidre Henderson said on Sunday. 'Utah—and our nation—are better because of her courageous work and unwavering belief in the American Dream.' PREVIOUSLY: Former Utah Rep. Mia Love has passed away, family confirms Henderson has previously discussed how she and the former congresswoman were close friends. Also on Sunday, Utah Gov. Spencer Cox took to social media to share his condolences. 'A true trailblazer and visionary leader, Mia inspired countless Utahns through her courage, grace, and unwavering belief in the American dream,' Gov. Cox . 'Her legacy leaves a lasting, positive impact on our state. We will miss her deeply.' Love's death was announced by her family on March 23, 2025, almost three weeks after the initial announcement that she was no longer responding to treatment. The Associated Press contributed to this report. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
CNN
29-01-2025
- Health
- CNN
A rare brain disorder robbed Robert F. Kennedy Jr. of his strong speaking voice
Robert F. Kennedy Jr.'s halting, gruff speaking voice, which at times can make him hard to understand, has been front and center during his confirmation hearing Wednesday as President Donald Trump's nominee to lead the US Department of Health and Human Services. Kennedy's vocal rasp is not caused by an infection or respiratory condition. Instead, he has spasmodic dysphonia, a rare neurological condition in which the muscles that open and close his vocal cords spasm involuntarily, creating a strained or strangled quality to his speech. Kennedy, 71, has publicly discussed how the condition robbed him of his typically strong speaking voice in his early 40s. 'At that time, I was making a lot of my income doing public speaking, and I could speak to large halls without any amplification,' Kennedy said in a February 2024 interview while running for president. 'When I was 42 years old, I got struck with a disease, a neurological disease, an injury called spasmodic dysphonia, and it makes my voice tremble,' he said, adding that 'I think it makes it problematical for people to listen to me. I cannot listen to myself on TV.' Muscle contraction disorder begins in the brain Spasmodic dysphonia affects up to 50,000 people in North America, and is a subset of dystonia, a muscle contraction disorder that can affect many parts of the body. In one type of vocal dystonia called lingual protrusion dystonia, a person's tongue can protrude when they try to speak, strangling their words. The most common form, cervical dystonia, affects the neck, causing wobbling or worse, the inability to hold the head upright. Blepharospasm, another kind of dystonia, is a forced squeezing shut of the eyelids that reduces or blocks vision. Still other types of dystonia can focus on the legs, hands and feet, even the entire body. While the disorder is relatively unknown, as many as 250,000 Americans have some type of dystonia, according to the American Association of Neurological Surgeons. It's the third most common movement disorder behind essential tremor and Parkinson's disease. Dystonia is thought to begin in the part of the brain called the basal ganglia that controls how muscles contract. When the condition strikes, that signal is distorted, causing muscles to move involuntarily or get stuck in an abnormal position. Treatments for dystonia are limited. Some medications can help distract the brain, and those are usually tried first. Deep-brain stimulation is a last resort for all but those with widespread dystonia in many body parts, which, sadly, are often children, experts say. Physical and speech therapy are usually a part of the treatment plan; acupuncture and medication may also help. 'A small number of people, maybe 5%, will find that it goes away just like it came, and we don't really know why,' neurologist Dr. Hyder Jinnah told CNN in an earlier interview. 'Most people have it for most of their life once it starts, and so we have to figure out ways to treat it,' said Jinnah, a professor of neurology and human genetics at Emory University in Atlanta. Injections of botulism toxin relax muscles; it is often the treatment of choice for some types of dystonia, such as blepharospasm. 'It doesn't treat the disorder; it treats their phenomena,' Dr. Andrew Blitzer, an otolaryngologist at Mount Sinai in New York City, told CNN previously. 'We can't change the brain signal coming in to the muscle, but we can weaken the muscle so it can't go into spasm.' Attacks the part of the body used most For a reason no doctor understands, dystonia often attacks the part of the body a person uses most for his or her profession. Diane Rehm, who was a nationally known radio talk-show host for decades and now has a podcast, has a form of dystonia that affects her vocal cords. 'How can you have a disorder where everything about the brain and the hand functions normally except the hand can't perform one exquisite task like writing or playing a musical instrument?' New York neurologist Dr. Steven Frucht, director of the division of Parkinson's and Movement Disorders at NYU Langone Health, told CNN in an earlier interview. A violinist and pianist himself, Frucht treats many musicians with the disorder. Trumpet players will suddenly be unable to use their lips. Guitar players, writers and pianists will lose control of fingers or an entire hand. 'You would think that this cannot happen,' Frucht said. 'And yet after seeing hundreds of patients, I can say it most certainly can. And it does.' Spasmodic dysphonia, or SD, can dramatically affect the lives of those who develop it, according to Dysphonia International, a nonprofit educational and support organization. 'Many individuals with SD feel that their voices don't accurately portray emotions, personality, and competence,' according to its website. 'Individuals experience physical, emotional, and functional losses including emotional distress, loss of job or salary, forced career change, reduced social participation, and negative changes in personal relationships due to spasmodic dysphonia.'
